Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Durata Prices IPO Of 7.5 Mln Shares At $9.00/shr, Before Underwriting Discounts

RELATED NEWS
Trade DRTX now with 
7/19/2012 8:41 AM ET

Durata Therapeutics (DRTX: Quote) announced the pricing of its initial public offering of 7.5 million shares of common stock at a public offering price of $9.00 per share, before underwriting discounts.

The shares are scheduled to commence trading on the NASDAQ Global Market on July 19, 2012 under the ticker symbol "DRTX", noted the company.

Durata further stated that the underwriters have an option for a period of 30 days to buy up to an additional 1.13 million shares of common stock from the company at the public offering price, less the underwriting discount. The offering is expected to close on or about July 24, 2012.

Click here to receive FREE breaking news email alerts for Durata Therapeutics and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
With traders digesting remarks from Federal Reserve Chairman Ben Bernanke, stocks have seen considerable volatility over the course of the trading day on Wednesday but are moving mostly higher in mid-day trading. The major averages have moved to the upside in recent trading and are currently posting notable gains. Comprehensive immigration reform legislation took a step toward approval on Tuesday, as the members of the Senate Judiciary Committee voted to send the bill to the Senate floor. The Senate Judiciary Committee voted 13 to 5 in favor of the bill, with three Republicans joining with the panel's ten Democrats in voting to support the legislation. Existing home sales in the U.S. saw a modest increase in the month of April, according to a report released by the National Association of Realtors on Wednesday. NAR said existing home sales climbed 0.6 percent to a seasonally adjusted annual rate of 4.97 million in April from an upwardly revised 4.94 million in March.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.